- Home
- ORC vs CVAC Comparison
ORC vs CVAC Comparison
Compare ORC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- CVAC
- Stock Information
- Founded
- ORC 2010
- CVAC 2000
- Country
- ORC United States
- CVAC Germany
- Employees
- ORC N/A
- CVAC N/A
- Industry
- ORC Real Estate Investment Trusts
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ORC Real Estate
- CVAC Health Care
- Exchange
- ORC Nasdaq
- CVAC Nasdaq
- Market Cap
- ORC 660.1M
- CVAC 764.4M
- IPO Year
- ORC 2013
- CVAC 2020
- Fundamental
- Price
- ORC $6.82
- CVAC $4.47
- Analyst Decision
- ORC Buy
- CVAC Strong Buy
- Analyst Count
- ORC 4
- CVAC 2
- Target Price
- ORC $9.50
- CVAC $14.00
- AVG Volume (30 Days)
- ORC 3.6M
- CVAC 778.1K
- Earning Date
- ORC 07-24-2025
- CVAC 05-20-2025
- Dividend Yield
- ORC 21.08%
- CVAC N/A
- EPS Growth
- ORC N/A
- CVAC N/A
- EPS
- ORC 0.46
- CVAC 0.87
- Revenue
- ORC $52,240,000.00
- CVAC $566,039,775.00
- Revenue This Year
- ORC $46.17
- CVAC N/A
- Revenue Next Year
- ORC $26.45
- CVAC $37.79
- P/E Ratio
- ORC $14.89
- CVAC $5.17
- Revenue Growth
- ORC N/A
- CVAC 787.60
- 52 Week Low
- ORC $5.69
- CVAC $2.37
- 52 Week High
- ORC $9.01
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- ORC 39.47
- CVAC 65.61
- Support Level
- ORC $6.70
- CVAC $3.35
- Resistance Level
- ORC $7.11
- CVAC $4.80
- Average True Range (ATR)
- ORC 0.15
- CVAC 0.30
- MACD
- ORC -0.02
- CVAC 0.07
- Stochastic Oscillator
- ORC 20.25
- CVAC 77.51
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.